Free Trial

Assertio (ASRT) Competitors

Assertio logo
$0.77 +0.05 (+6.49%)
Closing price 07/23/2025 04:00 PM Eastern
Extended Trading
$0.76 -0.01 (-1.04%)
As of 05:45 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ASRT vs. PRQR, INZY, TRDA, ACB, IMMP, NBTX, FENC, TKNO, EDIT, and SCPH

Should you be buying Assertio stock or one of its competitors? The main competitors of Assertio include ProQR Therapeutics (PRQR), Inozyme Pharma (INZY), Entrada Therapeutics (TRDA), Aurora Cannabis (ACB), Prima BioMed (IMMP), Nanobiotix (NBTX), Adherex Technologies (FENC), Alpha Teknova (TKNO), Editas Medicine (EDIT), and scPharmaceuticals (SCPH). These companies are all part of the "pharmaceutical products" industry.

Assertio vs. Its Competitors

ProQR Therapeutics (NASDAQ:PRQR) and Assertio (NASDAQ:ASRT) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, media sentiment, earnings, profitability, analyst recommendations, valuation and risk.

Assertio has higher revenue and earnings than ProQR Therapeutics. ProQR Therapeutics is trading at a lower price-to-earnings ratio than Assertio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ProQR Therapeutics$20.46M11.16-$30.04M-$0.35-6.20
Assertio$124.96M0.59-$21.58M-$0.32-2.41

Assertio has a net margin of -25.72% compared to ProQR Therapeutics' net margin of -157.04%. Assertio's return on equity of -24.87% beat ProQR Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
ProQR Therapeutics-157.04% -53.49% -22.07%
Assertio -25.72%-24.87%-10.87%

ProQR Therapeutics currently has a consensus price target of $8.00, suggesting a potential upside of 268.66%. Assertio has a consensus price target of $2.75, suggesting a potential upside of 257.14%. Given ProQR Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe ProQR Therapeutics is more favorable than Assertio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ProQR Therapeutics
0 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
3.13
Assertio
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00

32.7% of ProQR Therapeutics shares are owned by institutional investors. Comparatively, 49.0% of Assertio shares are owned by institutional investors. 8.4% of ProQR Therapeutics shares are owned by insiders. Comparatively, 4.0% of Assertio shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

ProQR Therapeutics has a beta of 0.36, suggesting that its stock price is 64% less volatile than the S&P 500. Comparatively, Assertio has a beta of 0.29, suggesting that its stock price is 71% less volatile than the S&P 500.

In the previous week, ProQR Therapeutics' average media sentiment score of 0.00 equaled Assertio'saverage media sentiment score.

Company Overall Sentiment
ProQR Therapeutics Neutral
Assertio Neutral

Summary

Assertio beats ProQR Therapeutics on 8 of the 15 factors compared between the two stocks.

Get Assertio News Delivered to You Automatically

Sign up to receive the latest news and ratings for ASRT and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ASRT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ASRT vs. The Competition

MetricAssertioMED IndustryMedical SectorNASDAQ Exchange
Market Cap$69.26M$2.43B$5.57B$9.42B
Dividend YieldN/A1.80%4.05%3.99%
P/E Ratio-2.419.1428.1520.08
Price / Sales0.59540.89401.6884.07
Price / Cash14.73166.9336.1958.45
Price / Book0.615.168.625.83
Net Income-$21.58M$30.99M$3.24B$258.27M
7 Day Performance14.93%3.81%3.55%2.69%
1 Month Performance20.84%12.26%11.01%12.91%
1 Year Performance-49.34%0.95%35.56%21.81%

Assertio Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ASRT
Assertio
1.6323 of 5 stars
$0.77
+6.5%
$2.75
+257.1%
-52.5%$69.26M$124.96M-2.4120
PRQR
ProQR Therapeutics
2.1633 of 5 stars
$2.48
+6.9%
$8.00
+222.6%
+15.1%$260.92M$20.46M-7.09180
INZY
Inozyme Pharma
2.8834 of 5 stars
$4.00
flat
$11.75
+193.8%
N/A$258.25MN/A-2.3750
TRDA
Entrada Therapeutics
2.9145 of 5 stars
$6.80
+3.8%
$25.67
+277.5%
-62.8%$258.08M$172.22M8.40110
ACB
Aurora Cannabis
0.2731 of 5 stars
$4.58
+2.0%
N/A-20.4%$257.44M$246.72M41.641,130
IMMP
Prima BioMed
1.0211 of 5 stars
$1.69
+2.4%
$7.00
+314.2%
-17.6%$246.81M$5.14M0.002,021Positive News
Upcoming Earnings
NBTX
Nanobiotix
1.9259 of 5 stars
$5.15
-0.4%
$8.00
+55.3%
+8.9%$242.72M$39.18M0.00100Gap Down
FENC
Adherex Technologies
2.4838 of 5 stars
$8.79
+0.1%
$13.00
+47.9%
+30.3%$242.60M$47.54M-17.2410
TKNO
Alpha Teknova
2.1974 of 5 stars
$4.49
-6.7%
$12.00
+167.3%
+103.2%$239.95M$38.25M-9.35240News Coverage
Analyst Upgrade
EDIT
Editas Medicine
4.0725 of 5 stars
$2.85
-1.0%
$4.70
+64.9%
-38.3%$238.57M$32.31M-0.94230Gap Up
SCPH
scPharmaceuticals
4.415 of 5 stars
$4.48
+2.3%
$14.00
+212.5%
+9.1%$236.50M$36.33M-2.3530Positive News

Related Companies and Tools


This page (NASDAQ:ASRT) was last updated on 7/24/2025 by MarketBeat.com Staff
From Our Partners